Source-grounded facts extracted from Protagonist Therapeutics, Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Protagonist Therapeutics, Inc reported first quarter ended March 31, 2026 results: revenue License and collaboration revenue $ 56,368, net income Net income (loss) $ 3,783, EPS Diluted earnings (loss) per share $ 0.05.
“to $646.0 million as of December 31, 2025. Three Months Ended March 31, 2026 2025 (in thousands, except per share amounts) (Unaudited) License and collaboration revenue $ 56,368 $ 28,321 Research and development expense $ 46,739 $ 35,893 General and administrative expense $ 13,277 $ 11,738 Income tax benefit $ 1,502 $ - Net income (loss) $ 3,783 $ (11,655”
Suneel Gupta changed role as Executive Vice President, Clinical Development at Protagonist Therapeutics, Inc.
“Effective January 1, 2025, Suneel Gupta, Ph.D., Protagonist Therapeutics, Inc.’s Chief Development Officer, transitioned to Executive Vice President, Clinical Development.”
Daniel N. Swisher Jr. resigned as Member of the Board of Directors at Protagonist Therapeutics, Inc.
“On September 17, 2024, Daniel N. Swisher Jr., a member of the Board of Directors (the “Board”) of Protagonist Therapeutics, Inc. (the “Company”) and a member of the Audit Committee of the Board, resigned from the Board, effective September 17, 2024.”
Earnings Releases
Protagonist Therapeutics, Inc reported first quarter ended March 31, 2024 results: revenue $255.0 million, net income $207,340 thousand, EPS $3.26 per diluted share.
“) Basic earnings (loss) per share $ 3.41 $ (0.67 ) Diluted earnings (loss) per share $ 3.26 $ (0.67 ) · License and Collaboration Revenue : License and collaboration revenue of $255.0 million for March 31, 2024 consisted of: (i) $254.1 million of the $300.0 million transaction price for the Takeda Collaboration Agreement allocated to the rusfertide license delivered”
Earnings Releases
Protagonist Therapeutics, Inc reported financial results for the fourth quarter and full year ended December 31, 2023.
“On February 27, 2024, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023.”
Material Agreements
Protagonist Therapeutics, Inc entered into License and Collaboration Agreement with Takeda Pharmaceuticals USA, Inc. valued at $300 million (effective 2024-01-31).
“On January 31, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”) with Takeda Pharmaceuticals USA, Inc. (“ Takeda ”) for the development, manufacture and commercialization of the Company’s rusfertide product candidate”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.